login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock News
USA
- NYSE:TAK -
US8740602052
-
ADR
14.01
USD
-0.05 (-0.36%)
Last: 10/24/2025, 8:04:00 PM
14
USD
-0.01 (-0.07%)
After Hours:
10/24/2025, 8:04:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
TAK Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Innovent Biologics
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
3 days ago - By: Takeda Pharmaceutical Company Limited
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
11 days ago - By: Benzinga
Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact
15 days ago - By: Benzinga
- Mentions:
JNJ
PTGX
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
a month ago - By: Takeda Pharmaceutical Company Limited
20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
a month ago - By: The Motley Fool
- Mentions:
MO
PFE
XOM
BTI
5 Best High-Yield Dividend Stocks to Buy Now
a month ago - By: Takeda Pharmaceutical Company Limited
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
5 months ago - By: Zacks Investment Research
- Mentions:
GRFS
ADMA
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?
6 months ago - By: Zacks Investment Research
- Mentions:
MFG
LTM
FIVN
Top 4 GARP Stocks With Attractive PEG Ratios to Watch
a month ago - By: Takeda Pharmaceutical Company Limited
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
2 months ago - By: Takeda Pharmaceutical Company Limited
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025
2 months ago - By: Takeda Pharmaceutical Company Limited
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
2 months ago - By: Yahoo Finance
Takeda Pharmaceutical Company Limited (TAK) Advances γδ T Cell Cancer Treatments
3 months ago - By: Takeda Pharmaceutical Company Limited
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
3 months ago - By: Investor's Business Daily
- Mentions:
RY
RY.CA
ALKS
CNTA
...
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.
3 months ago - By: Takeda Pharmaceutical Company Limited
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
3 months ago - By: Yahoo Finance
Takeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA
3 months ago - By: Takeda Pharmaceutical Company Limited
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
4 months ago - By: Takeda Pharmaceutical Company Limited
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
4 months ago - By: Takeda Pharmaceutical Company Limited
Takeda Announces New Assignments of Directors
5 months ago - By: Takeda Pharmaceutical Company Limited
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
5 months ago - By: Takeda Pharmaceutical Company Limited
- Mentions:
PTGX
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
5 months ago - By: Takeda Pharmaceutical Company Limited
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
5 months ago - By: Yahoo Finance
- Mentions:
MSFT
VRT
NVDA
META
...
Build 2025 Highlights Microsoft (MSFT)’s Push Toward a Collaborative AI Future
5 months ago - By: Yahoo Finance
- Mentions:
NVDA
VRT
CMI
MSFT
...
Vertiv Enhances AI Infrastructure with NVIDIA (NVDA) 800V DC
5 months ago - By: Takeda Pharmaceutical Company Limited
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
6 months ago - By: Yahoo Finance
- Mentions:
AAPL
MSFT
C
US and China to slash tariffs for 90 days as Trump and Xi likely to talk 'maybe at the end of the week'
6 months ago - By: Investor's Business Daily
- Mentions:
GILD
PFE
NVS
ABBV
...
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
6 months ago - By: Zacks Investment Research
- Mentions:
GRFS
ADMA
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
Please enable JavaScript to continue using this application.